Bintrafusp alfa
- Generic Name
- Bintrafusp alfa
- Drug Type
- Biotech
- CAS Number
- 1918149-01-5
- Unique Ingredient Identifier
- NW9K8C1JN3
- Background
Bintrafusp alfa is under investigation in clinical trial NCT03833661 (M7824 Monotherapy in Locally Advanced or Metastatic Second Line (2L) Biliary Tract Cancer (Cholangiocarcinoma and Gallbladder Cancer)).
M7824 and Eribulin Mesylate in Treating Patients With Metastatic Triple Negative Breast Cancer
- Conditions
- Prognostic Stage IV Breast Cancer AJCC v8Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast Carcinoma
- Interventions
- First Posted Date
- 2018-07-06
- Last Posted Date
- 2022-10-31
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 38
- Registration Number
- NCT03579472
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
🇺🇸Lyndon Baines Johnson General Hospital, Houston, Texas, United States
M7824 and Topotecan or Temozolomide in Relapsed Small Cell Lung Cancers
- Conditions
- Carcinoma, Small CellLung CancerSmall Cell Lung Cancer
- Interventions
- Diagnostic Test: EKGDiagnostic Test: CT scanDiagnostic Test: PET scanDrug: Antihistamines
- First Posted Date
- 2018-06-13
- Last Posted Date
- 2025-05-09
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 37
- Registration Number
- NCT03554473
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Radiation Therapy and M7824 in Treating Patients With Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8Metastatic Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
- Interventions
- Radiation: Radiation Therapy
- First Posted Date
- 2018-05-14
- Last Posted Date
- 2022-03-07
- Lead Sponsor
- M.D. Anderson Cancer Center
- Target Recruit Count
- 24
- Registration Number
- NCT03524170
- Locations
- 🇺🇸
M D Anderson Cancer Center, Houston, Texas, United States
Phase I/II Study of Immunotherapy Combination BN-Brachyury Vaccine, M7824, N-803 and Epacadostat (QuEST1)
- Conditions
- Prostate CancerSolid TumorMetastatic Prostate CancerAdvanced Solid TumorProstate Neoplasm
- Interventions
- First Posted Date
- 2018-04-11
- Last Posted Date
- 2024-11-25
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 53
- Registration Number
- NCT03493945
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
M7824 (MSB0011359C) in Combination With Gemcitabine in Adults With Previously Treated Advanced Adenocarcinoma of the Pancreas
- Conditions
- Pancreatic AdenocarcinomaPancreatic NeoplasmsPancreas CancerCancer of PancreasPancreatic Cancer
- Interventions
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2021-06-16
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 7
- Registration Number
- NCT03451773
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
M7824 in Subjects With HPV Associated Malignancies
- Conditions
- Human Papilloma VirusCervical CancerAnal CancerOropharyngeal CancerVaginal or Penile Cancer
- Interventions
- First Posted Date
- 2018-02-09
- Last Posted Date
- 2023-03-28
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 57
- Registration Number
- NCT03427411
- Locations
- 🇺🇸
National Institutes of Health Clinical Center, Bethesda, Maryland, United States
Dose Escalation and Expansion Study of GSK3359609 in Participants With Selected Advanced Solid Tumors (INDUCE-1)
- Conditions
- Neoplasms
- Interventions
- First Posted Date
- 2016-03-31
- Last Posted Date
- 2024-12-27
- Lead Sponsor
- GlaxoSmithKline
- Target Recruit Count
- 829
- Registration Number
- NCT02723955
- Locations
- 🇪🇸
GSK Investigational Site, Sevilla, Spain
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.